A judge has ordered that the lead applicant in a class action against German cladding manufacturer 3A Composites give further details on how its allegedly combustible cladding caused losses for property owners.
A judge has signed off on a $44.5 million settlement of a shareholder class action against Woolworths, which includes a $4.73 million funding commission, but the amount of fees to be paid to the law firm running the case remains to be decided.
Samsung Bioepis Australia has sued fellow biotechnology company Fresenius Kabi over a biosimilar of top selling immunosuppressant drug Humira, saying the invention ādoes not achieve the promiseā of a better formulation using fewer ingredients.
Several lenders have appealed a ruling that found they failed to prove steel giant Arrium falsified representations on loan drawdown notices ahead of its $2.8 billion collapse, saying it was a āno brainerā that the company was in dire straits when its directors sought extra funds.
A former Greenwoods & Freehills partner will argue he is entitled to whistleblower protection in his lawsuit against the tax advisory firm and Lendlease, alleging he was forced to leave after refusing to put his name to a tax return and making protected disclosures.
The settlement figure in a class action against a unit of Suncorp Group has been revealed as $33 million, and super members are set to share in the net sum of $14 million, or 42.5 per cent of the deal.
Trading firm Epoch Capital has brought proceedings against a quantitative analyst who allegedly downloaded confidential information from the firmās computers.
Norton Rose Fulbright has lost the co-head of its energy, infrastructure and resources team in Australia to King & Wood Mallesons, just months after the group’s other leader jumped ship to another Big Six firm.
Korean drug company Samsung Bioepis has filed a second lawsuit seeking to invalidate German drug company Fresenius Kadi’s patent for a biosimilar of blockbuster arthritis drug Humira.
The law firm that lost the first ever application for a group costs order in class actions against ANZ and Westpac has indicated it will revive its bid, tweaking a retainer agreement with group members in hopes of winning the court’s approval this time.